Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, +42

New England Journal of Medicine

Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: role of cigarette smoking

Kyoji Takaoka, Michihiro Yoshimura, Hisao Ogawa, +6

International Journal of Cardiology

Tobacco ControlCardiovascular EpidemiologyHealth PolicyCardiovascular DiseaseAtherosclerosis +11

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

Alexander Drilon, Geoffrey R. Oxnard, Lori J. Wirth, +65

Journal of Thoracic Oncology

Phase 1/2Pl02.08 Registrational ResultsMedicinePathologyBronchial Neoplasm +6

Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations

Eiji Iwama, Yoshitaka Zenke, Shunichi Sugawara, +10

European Journal of Cancer

Cell Lung CancerMedicineCancer GrowthPathologyCancer Treatment +7

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations

Yusuke Okuma, Kaoru Kubota, Mototsugu Shimokawa, +8

JAMA Oncology

Phase II study of tepotinib in NSCLC patients with <i>MET</i>ex14 mutations.

Paul K. Paik, Rémi Veillon, Alexis B. Cortot, +17

Journal of Clinical Oncology

PathologyPhase Ii StudyOncologyMetronomic TherapyMolecular Diagnostics +15

Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer

Yoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, +25

JAMA Oncology

DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair.

Masaaki Yanai, Haruhiko Makino, Bingqiong Ping, +8

PubMed

Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non–Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)

Naoki Haratake, Hidetoshi Hayashi, Mototsugu Shimokawa, +9

Clinical Lung Cancer

L858r MutationMedicineImmunologyPathologyCancer Treatment +6

Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer

Tomohiro Sakamoto, Taichi Matsubara, Takayuki Takahama, +21

JAMA Network Open